vs

Side-by-side financial comparison of BayCom Corp (BCML) and Editas Medicine, Inc. (EDIT). Click either name above to swap in a different company.

BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $24.7M, roughly 1.0× Editas Medicine, Inc.). BayCom Corp runs the higher net margin — 26.5% vs -22.7%, a 49.2% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs -19.2%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-36.4M). Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs 2.9%).

BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

BCML vs EDIT — Head-to-Head

Bigger by revenue
BCML
BCML
1.0× larger
BCML
$25.9M
$24.7M
EDIT
Growing faster (revenue YoY)
BCML
BCML
+28.6% gap
BCML
9.4%
-19.2%
EDIT
Higher net margin
BCML
BCML
49.2% more per $
BCML
26.5%
-22.7%
EDIT
More free cash flow
BCML
BCML
$66.5M more FCF
BCML
$30.1M
$-36.4M
EDIT
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
2.9%
BCML

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCML
BCML
EDIT
EDIT
Revenue
$25.9M
$24.7M
Net Profit
$6.9M
$-5.6M
Gross Margin
Operating Margin
36.6%
-31.3%
Net Margin
26.5%
-22.7%
Revenue YoY
9.4%
-19.2%
Net Profit YoY
12.1%
87.6%
EPS (diluted)
$0.63
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCML
BCML
EDIT
EDIT
Q4 25
$25.9M
$24.7M
Q3 25
$25.7M
$7.5M
Q2 25
$24.7M
$3.6M
Q1 25
$24.3M
$4.7M
Q4 24
$23.7M
$30.6M
Q3 24
$25.6M
$61.0K
Q2 24
$23.8M
$513.0K
Q1 24
$24.5M
$1.1M
Net Profit
BCML
BCML
EDIT
EDIT
Q4 25
$6.9M
$-5.6M
Q3 25
$5.0M
$-25.1M
Q2 25
$6.4M
$-53.2M
Q1 25
$5.7M
$-76.1M
Q4 24
$6.1M
$-45.4M
Q3 24
$6.0M
$-62.1M
Q2 24
$5.6M
$-67.6M
Q1 24
$5.9M
$-62.0M
Operating Margin
BCML
BCML
EDIT
EDIT
Q4 25
36.6%
-31.3%
Q3 25
26.3%
-325.4%
Q2 25
35.3%
-1440.6%
Q1 25
31.6%
-1635.1%
Q4 24
34.2%
-152.2%
Q3 24
32.4%
-107649.2%
Q2 24
31.9%
-14016.2%
Q1 24
33.3%
-5902.3%
Net Margin
BCML
BCML
EDIT
EDIT
Q4 25
26.5%
-22.7%
Q3 25
19.5%
-333.0%
Q2 25
25.8%
-1487.8%
Q1 25
23.4%
-1633.5%
Q4 24
25.9%
-148.3%
Q3 24
23.5%
-101870.5%
Q2 24
23.6%
-13178.8%
Q1 24
24.0%
-5458.1%
EPS (diluted)
BCML
BCML
EDIT
EDIT
Q4 25
$0.63
$0.03
Q3 25
$0.46
$-0.28
Q2 25
$0.58
$-0.63
Q1 25
$0.51
$-0.92
Q4 24
$0.55
$-0.55
Q3 24
$0.54
$-0.75
Q2 24
$0.50
$-0.82
Q1 24
$0.51
$-0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCML
BCML
EDIT
EDIT
Cash + ST InvestmentsLiquidity on hand
$146.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$338.6M
$27.3M
Total Assets
$2.6B
$186.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCML
BCML
EDIT
EDIT
Q4 25
$146.6M
Q3 25
$165.6M
Q2 25
$178.5M
Q1 25
$221.0M
Q4 24
$269.9M
Q3 24
$265.1M
Q2 24
$279.1M
Q1 24
$296.2M
Total Debt
BCML
BCML
EDIT
EDIT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$57.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BCML
BCML
EDIT
EDIT
Q4 25
$338.6M
$27.3M
Q3 25
$334.3M
$13.5M
Q2 25
$330.6M
$19.2M
Q1 25
$329.3M
$62.4M
Q4 24
$324.4M
$134.3M
Q3 24
$321.7M
$175.6M
Q2 24
$315.3M
$232.0M
Q1 24
$314.2M
$294.4M
Total Assets
BCML
BCML
EDIT
EDIT
Q4 25
$2.6B
$186.5M
Q3 25
$2.6B
$201.8M
Q2 25
$2.6B
$210.6M
Q1 25
$2.6B
$263.7M
Q4 24
$2.7B
$341.6M
Q3 24
$2.6B
$327.6M
Q2 24
$2.6B
$384.8M
Q1 24
$2.6B
$440.3M
Debt / Equity
BCML
BCML
EDIT
EDIT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.43×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCML
BCML
EDIT
EDIT
Operating Cash FlowLast quarter
$31.8M
$-36.4M
Free Cash FlowOCF − Capex
$30.1M
$-36.4M
FCF MarginFCF / Revenue
116.2%
-147.3%
Capex IntensityCapex / Revenue
6.7%
0.2%
Cash ConversionOCF / Net Profit
4.64×
TTM Free Cash FlowTrailing 4 quarters
$51.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCML
BCML
EDIT
EDIT
Q4 25
$31.8M
$-36.4M
Q3 25
$7.3M
$-30.8M
Q2 25
$6.4M
$-50.2M
Q1 25
$9.3M
$-47.8M
Q4 24
$30.4M
$-50.8M
Q3 24
$9.6M
$-52.6M
Q2 24
$7.7M
$-57.1M
Q1 24
$5.1M
$-49.9M
Free Cash Flow
BCML
BCML
EDIT
EDIT
Q4 25
$30.1M
$-36.4M
Q3 25
$6.2M
$-31.3M
Q2 25
$5.6M
Q1 25
$9.1M
$-47.9M
Q4 24
$28.7M
$-51.3M
Q3 24
$9.4M
$-55.5M
Q2 24
$7.4M
$-60.6M
Q1 24
$3.9M
$-51.7M
FCF Margin
BCML
BCML
EDIT
EDIT
Q4 25
116.2%
-147.3%
Q3 25
24.3%
-414.6%
Q2 25
22.8%
Q1 25
37.6%
-1028.6%
Q4 24
121.1%
-167.6%
Q3 24
36.6%
-90998.4%
Q2 24
31.2%
-11804.3%
Q1 24
16.1%
-4558.9%
Capex Intensity
BCML
BCML
EDIT
EDIT
Q4 25
6.7%
0.2%
Q3 25
4.3%
5.7%
Q2 25
3.0%
0.0%
Q1 25
0.6%
2.4%
Q4 24
7.2%
1.8%
Q3 24
1.0%
4788.5%
Q2 24
1.0%
681.1%
Q1 24
4.7%
164.8%
Cash Conversion
BCML
BCML
EDIT
EDIT
Q4 25
4.64×
Q3 25
1.47×
Q2 25
1.00×
Q1 25
1.63×
Q4 24
4.96×
Q3 24
1.60×
Q2 24
1.37×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons